Victory Capital Management’s Integra LifeSciences IART Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$470K Sell
26,143
-172,240
-87% -$2.41M ﹤0.01% 2089
2026
Q1
$1.87M Buy
198,383
+27,095
+16% +$297K ﹤0.01% 1616
2025
Q4
$2.13M Buy
171,288
+99,382
+138% +$1.32M ﹤0.01% 1570
2025
Q3
$1.03M Sell
71,906
-258,992
-78% -$3.55M ﹤0.01% 1827
2025
Q2
$4.06M Buy
330,898
+182,916
+124% +$2.66M ﹤0.01% 1375
2025
Q1
$3.25M Buy
147,982
+135,308
+1,068% +$3.18M ﹤0.01% 1409
2024
Q4
$287K Sell
12,674
-9,832
-44% -$215K ﹤0.01% 2150
2024
Q3
$409K Sell
22,506
-3,114
-12% -$72.2K ﹤0.01% 2064
2024
Q2
$747K Sell
25,620
-342,084
-93% -$10.1M ﹤0.01% 1838
2024
Q1
$13M Buy
367,704
+353,733
+2,532% +$14.1M 0.01% 973
2023
Q4
$608K Sell
13,971
-1,451,144
-99% -$57.1M ﹤0.01% 1939
2023
Q3
$56M Buy
1,465,115
+238,816
+19% +$10M 0.06% 386
2023
Q2
$50.4M Sell
1,226,299
-3,765
-0.3% -$181K 0.06% 427
2023
Q1
$70.6M Buy
1,230,064
+1,215,259
+8,208% +$68.5M 0.08% 330
2022
Q4
$830K Sell
14,805
-8,469
-36% -$431K ﹤0.01% 1824
2022
Q3
$986K Sell
23,274
-6,474
-22% -$332K ﹤0.01% 1743
2022
Q2
$1.61M Sell
29,748
-79
-0.3% -$4.74K ﹤0.01% 1536
2022
Q1
$1.82M Buy
29,827
+7,788
+35% +$513K ﹤0.01% 1537
2021
Q4
$1.48M Buy
22,039
+42
+0.2% +$2.84K ﹤0.01% 1665
2021
Q3
$1.51M Sell
21,997
-905
-4% -$63.9K ﹤0.01% 1685
2021
Q2
$1.56M Buy
22,902
+6,011
+36% +$425K ﹤0.01% 1706
2021
Q1
$1.17M Buy
16,891
+8,138
+93% +$551K ﹤0.01% 1852
2020
Q4
$568K Sell
8,753
-7,194
-45% -$387K ﹤0.01% 2017
2020
Q3
$753K Sell
15,947
-8,263
-34% -$393K ﹤0.01% 1824
2020
Q2
$1.14M Buy
24,210
+1,297
+6% +$63.8K ﹤0.01% 1669
2020
Q1
$1.02M Buy
22,913
+2,560
+13% +$134K ﹤0.01% 1592
2019
Q4
$1.19M Buy
20,353
+9,423
+86% +$561K ﹤0.01% 1692
2019
Q3
$657K Buy
+10,930
New +$651K ﹤0.01% 1801
2019
Q1
Sell
-62,841
Closed -$2.83M 1820
2018
Q4
$2.83M Sell
62,841
-242
-0.4% -$13.3K 0.01% 951
2018
Q3
$4.16M Buy
+63,083
New +$3.92M 0.01% 917
2018
Q1
Sell
-347,506
Closed -$16.6M 1866
2017
Q4
$16.6M Sell
347,506
-405,025
-54% -$19.8M 0.04% 619
2017
Q3
$38M Sell
752,531
-260,530
-26% -$13.4M 0.09% 372
2017
Q2
$55.2M Sell
1,013,061
-275,065
-21% -$13.1M 0.13% 257
2017
Q1
$54.3M Sell
1,288,126
-149,680
-10% -$6.4M 0.13% 272
2016
Q4
$61.7M Sell
1,437,806
-105,010
-7% -$4.27M 0.16% 223
2016
Q3
$63.7M Buy
+1,542,816
New +$64.6M 0.18% 188
2016
Q2
Sell
-655,918
Closed -$22.1M 1651
2016
Q1
$22.1M Sell
655,918
-77,160
-11% -$2.4M 0.09% 382
2015
Q4
$24.8M Sell
733,078
-363,260
-33% -$11.4M 0.1% 335
2015
Q3
$32.6M Sell
1,096,338
-338,596
-24% -$10.6M 0.13% 253
2015
Q2
$39.5M Sell
1,434,934
-591,807
-29% -$15.8M 0.15% 228
2015
Q1
$51.1M Sell
2,026,741
-74,495
-4% -$1.76M 0.18% 185
2014
Q4
$46.6M Buy
2,101,236
+36,110
+2% +$732K 0.17% 192
2014
Q3
$41.9M Buy
2,065,126
+109,602
+6% +$2.18M 0.32% 104
2014
Q2
$37.6M Buy
1,955,524
+151,804
+8% +$2.83M 0.26% 139
2014
Q1
$33.9M Buy
1,803,720
+216,963
+14% +$4.19M 0.23% 162
2013
Q4
$30.9M Buy
1,586,757
+452,947
+40% +$8.31M 0.22% 158
2013
Q3
$18.7M Buy
+1,133,810
New +$18.2M 0.13% 227

Other funds holding IART

Victory Capital Management's IART Position: Q2 2026 in Review

Victory Capital Management reduced its Integra LifeSciences (IART) stake by 87% in Q2 2026, selling an estimated $2.41M and leaving 26,143 shares worth $470K. The position accounts for ﹤0.01% of the portfolio, ranked #2089.

Victory Capital Management first reported a position in IART in Q3 2013 and has held it in 47 quarters since. The position peaked at $70.6M in Q1 2023. 212 funds tracked by Wall St. Rank hold IART as of Q2 2026.

  • Victory Capital Management held 26,143 shares of Integra LifeSciences worth $470K as of Q2 2026.
  • Victory Capital Management sold 172,240 Integra LifeSciences shares in Q2 2026, an estimated $2.41M.
  • Integra LifeSciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2089 holding.
  • Victory Capital Management first reported a position in Integra LifeSciences in Q3 2013 and has held it in 47 quarters since.
  • Victory Capital Management's Integra LifeSciences position peaked at $70.6M in Q1 2023.
  • 212 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.